InMed Pharmaceuticals reported financial results for Q1 fiscal 2025 ended September 30, 2024, with revenue increasing 40% to $1.3 million compared to $902,000 in Q1 2024. The company's net loss narrowed to $1.7 million from $2.5 million year-over-year, while gross profit improved significantly to $493,000 from $21,000. Cash and equivalents stood at $5.6 million as of September 30, 2024.The company made notable progress in its pharmaceutical pipeline, particularly with INM-901 for Alzheimer's disease. Preclinical studies demonstrated INM-901's oral formulation achieves therapeutic brain levels comparable to intraperitoneal injection. Long-term studies showed positive behavioral trends in treated groups, with statistically significant improvements in certain criteria versus placebo groups.Research and development expenses decreased 40% to $771,000 due to lower external contractor and patent costs. The BayMedica commercial segment saw strong growth with sales up 40% year-over-year, driven by expanded marketing efforts and increased demand. Management expects current cash reserves to fund operations through Q1 2025, while pursuing additional financing options and strategic partnerships.

InMed Pharmaceuticals reported financial results for Q1 fiscal 2025 ended September 30, 2024, with revenue increasing 40% to $1.3 million compared to $902,000 in Q1 2024. The company's net loss narrowed to $1.7 million from $2.5 million year-over-year, while gross profit improved significantly to $493,000 from $21,000. Cash and equivalents stood at $5.6 million as of September 30, 2024.The company made notable progress in its pharmaceutical pipeline, particularly with INM-901 for Alzheimer's disease. Preclinical studies demonstrated INM-901's oral formulation achieves therapeutic brain levels comparable to intraperitoneal injection. Long-term studies showed positive behavioral trends in treated groups, with statistically significant improvements in certain criteria versus placebo groups.Research and development expenses decreased 40% to $771,000 due to lower external contractor and patent costs. The BayMedica commercial segment saw strong growth with sales up 40% year-over-year, driven by expanded marketing efforts and increased demand. Management expects current cash reserves to fund operations through Q1 2025, while pursuing additional financing options and strategic partnerships.